Online Management of Breast Diseases Patient Education |  Physician Guidelines |  Treatment Index
News |  TransMed |  E-Mail |  Disclaimer

Onc.Protocol:NAVELBINE

 

 

ONCOLOGIC PROTOCOL

NAVELBINE - STAGE IV

MAJOR INDICATIONS: TREATMENTS FOR STAGE IV BREAST CANCER
IDENTIFICATION: Vinorelbine (Navelbine)
This drug has not been approved by the FDA (Food and Drug Administration) for the treatment of breast cancer, but there is evidence from clinical trials that it is effective against breast cancer.
Doses: 30 mg./M2
Route: Given intravenously (IV)
Duration and timing: Given once a week
Treatments are generally continued as long as the drug keeps the breast cancer from growing unless there are unacceptable side effects.
Possible Side effects:
  • Hematopoetic: decrease in blood cells, especially white cells (neutropenia) but also red cells (anemia) and or platelets (thrombocytopenia)
  • Gastrointestinal: possible nausea and vomiting (which may be decreased or prevented with medications); constipation; mouth sores; decreased appetite; abnormalities in liver function tests
  • Integmentary: hair thinning; if the drug leaks outside the vein it may damage the skin and cause scarring
  • Fertility: effect on fertility is unknown; this drug should not be taken by women who are pregnant or breast feeding
  • Cardiovascular: irritation to the vein where the drug is given (phlebitis); chest pain is a rare side effect and occurs most often in patients with a history of cardiovascular disease
  • Respiratory: shortness of breath and/or cough are rare side effects
  • Neurological: numbness, tingling and/or burning sensations in hands and/or feet (peripheral neuropathy); jaw pain; tumor pain; weakness in the hands or feet
  • Other: fatigue; muscle aches (myalgia)

Back gif

 

1997 - TransMed Network